Find clinical trials for Leukemia in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia

Acute Myeloid Leukemia

Lymphoid Leukemia

B-Cell Chronic Lymphocytic Leukemia

Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Myelodysplastic Syndromes

Leukemia trials near Cincinnati, OH, USA:

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling

Acute Leukemia of Ambiguous Lineage

Mixed Phenotype Acute Leukemia

Drug: revumenib

Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals

Cincinnati, Ohio, United States and 47 other locations

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting

Acute Myeloid Leukemia

Drug: Gilteritinib

Drug: Daunorubicin

Phase 2

PrECOG

Cincinnati, Ohio, United States and 43 other locations

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting

Leukemia

Drug: Methotrexate

Drug: Thioguanine

Phase 2

Incyte

Cincinnati, Ohio, United States and 110 other locations

Locations recently updated

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling

Myeloid Leukemia, Philadelphia Positive

Drug: Asciminib Adult formulation group

Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis

Cincinnati, Ohio, United States and 35 other locations

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...

Active, not recruiting

Leukemia, Myeloid, Acute

Leukemia, Myelomonocytic, Chronic

Drug: Pevonedistat

Drug: Azacitidine

Phase 3

Takeda

Cincinnati, Ohio, United States and 240 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...

Active, not recruiting

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Drug: Nilotinib

Drug: Asciminib

Phase 3

Novartis

Cincinnati, Ohio, United States and 120 other locations

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed ...

Active, not recruiting

Acute Myeloid Leukemia

Drug: TL-895

Drug: KRT-232

Phase 1, Phase 2

Telios Pharma

Cincinnati, Ohio, United States and 34 other locations

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when g...

Active, not recruiting

Acute Myeloid Leukemia (AML)

Cancer

Drug: Venetoclax

Drug: Azacitidine

Phase 3

AbbVie

Cincinnati, Ohio, United States and 164 other locations

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2...

Enrolling

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

Acute Myeloid Leukemia (AML)

Drug: fludarabine

Drug: granulocyte colony-stimulating factor (G-CSF)

Phase 1, Phase 2

Astellas

Cincinnati, Ohio, United States and 24 other locations

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling

Leukemia, Lymphocytic, Chronic, B-Cell

Small Lymphocytic Lymphoma

Drug: Venetoclax

Drug: Ibrutinib

Phase 2

Janssen (J&J Innovative Medicine)

Cincinnati, Ohio, United States of America and 59 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Leukemia in .css-epvm6{white-space:nowrap;}Cincinnati, OH

Related conditions:

Leukemia trials near Cincinnati, OH, USA:

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Find clinical trials for Leukemia in Cincinnati, OH